I’m doing a series of interviews with leaders in the field on human germline modification with the first interview in this series with George Church and today’s second in this series is a conversation I had with Dr. Jennifer Doudna, a pioneer in CRISPR-Cas9 technology. Doudna is a Professor in MCB and Chemistry as well […]
Jennifer Doudna Interview on CRISPR, Human Gene Editing Read More »
CRISPR Cas9 is a relatively new, powerful approach to gene editing and genetic modification more generally. In the relatively short window of time in which this technology has been widely available for gene editing applications it has already evolved rapidly to become more powerful. Here are some new papers of interest on this technology. With
5 new cool papers on CRISPR Cas9 gene editing Read More »
Post-publication (post-pub) review is arguably one of the most innovative developments in scientific publishing in the past few years, including at the site PubPeer. An illustration of the widespread influence of post-pub review is the fact that PubMed recently started allowing readers to post comments about any paper. Post-pub review drove the rapid debunking of the
Will Lawsuit Against PubPeer Chill Post-Pub Review? Read More »
Stem cell-based Regenerative Medicine has huge power for good in the clinic and at the same time great potential for economic development. Those two things go hand in hand. As I argued in my stem cell book, biotech commercialization of stem cells is not a bad thing, but rather if it is done responsibly it
Reflecting on Regenerative Medicine As A Brand Read More »
One of the more controversial areas in the stem cell field has been over a stem cell type that only a handful of researchers have been able to find and study: very small embryonic-like stem cells or VSELs. These days some are calling them V-cells too. I’ve been getting an increasing number of questions from
What are VSELs and why are more clinics selling them? Read More »